Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00357591
Other study ID # IDEG020301
Secondary ID
Status Terminated
Phase N/A
First received July 25, 2006
Last updated December 24, 2009
Start date September 2004
Est. completion date January 2008

Study information

Verified date August 2009
Source Orqis Medical Corporation
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The Company's proprietary products are based on Orqis Medical's hypothesis, supported by early clinical data, that increasing and maintaining continuous blood flow in the descending aorta, known as continuous aortic flow augmentation or CAFA, improves hemodynamics in heart failure patients. The clinical impact of the hemodynamic improvement is currently being evaluated to determine the effects of CAFA on stopping or reversing the progression of heart failure through three physiological effects:

- VASCULAR - Reducing systemic vascular resistance

- RENAL - Improving renal function

- CARDIAC - Reducing cardiac workload


Recruitment information / eligibility

Status Terminated
Enrollment 200
Est. completion date January 2008
Est. primary completion date January 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

1. Patients hospitalized due to decompensated heart failure who require IV inotropic and/or vasodilator and diuretic therapy

2. Patients receiving appropriate medical therapy for heart failure, defined as ACE inhibitors and beta blockers (all unless not tolerated or contraindicated) and diuretics, for 1 month prior to study entry

3. For at least 24 hours prior to inclusion into the study, the patient should be treated with a minimum dose of the following: dobutamine 2.5µg/kg/min or milrinone 0.3µg/kg/min or dopamine 5µg/kg/min. or nesiritide 0.01µg/kg/min or nitroglycerin 0.3 µg/kg/min or nitroprusside 0.3 µg/kg/min or a combination of any of these agents, with diuretic therapy. Doses of the above stated medications should be stable for 6 hours prior to inclusion into study. An increase in this dosage within the first 8 hours after enrollment is determined by the attending physician to be unlikely and the following definition of "not responding adequately to IV inotropic and/or vasodilator and diuretic therapy" is exhibited:

- PCWP is = 20 mmHg at time of randomization and PCWP was = 18 mmHg continuously for 24 hours or PCWP = 20 mmHg continuously for 12 hours prior to randomization.

- Cardiac Index < 2.4 L/min/m2

- There is evidence for abnormal renal function and/or diuretic resistance defined as: Serum creatinine > 1.2 mg/dL or Diuretic dosage of intravenous Furosemide = 120 mg daily, or equivalent

4. LVEF < 35%

5. Male or female 18-90 years of age

6. If female, no child-bearing potential or negative pregnancy test

7. Written informed consent

8. Willingness to participate in required follow-up exams

Exclusion Criteria:

1. Acute Q-wave myocardial infarction within past 7 days

2. Post cardiotomy shock within past 30 days

3. Cardiac surgery within past 14 days

4. Bridge to transplant

5. History of severe COPD as defined as FEV1 < 1.0 liter

6. History of malignant arrhythmias defined as either:

- sustained ventricular tachycardia > 15 beats or more in length, not associated with a correctable cause, within the preceding 3 months, unless the patient presently has an implantable cardiac defibrillator.

- history of ventricular fibrillation or sudden death, unless the patient presently has an implantable cardiac defibrillator

7. Patients implanted with a resynchronization device within the previous 14 days or if there is a possibility of implant within 60 days following randomization

8. Systolic pressure <80 mmHg

9. Requiring cardiopulmonary support type devices

10. Platelets < 50,000/mm3 or other evidence of coagulopathy, INR greater than 1.5 in the absence of anticoagulation therapy.

11. Infection (WBC = 12.5 x 103/ml, and or temperature = 100.5°F/38°C)

12. History of cerebral vascular accident (CVA) or transient ischemic attacks (TIA) within the last 3 months

13. Unwilling or unable to receive blood transfusion

14. Inability to undergo treatment with heparin

15. Patients on dialysis or serum creatinine > 4.0 mg/dl

16. Primary liver disease with bilirubin, SGOT, or SGPT > 4X upper limit of normal

17. Life expectancy from other disease < 12 months

18. Patients who are active on the cardiac transplantation waiting list, unless there is a documented reason (large body habitus, highly sensitized, O blood group) to anticipate that transplant is unlikely within the subsequent 65 days.

19. Symptomatic patent foramen ovale or intracardiac shunt

20. Patients diagnosed with clinically significant peripheral vascular disease, defined as absent pedal pulse or signs or symptoms of limb ischemia, including a history of intermittent claudication

21. Patients with amyloidosis, thyroid induced heart failure, high output failure secondary to an arterio-venous fistula, and significant uncorrected primary valvular disease (with the exception of mitral regurgitation believed secondary to LV dilatation)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Continuous Aortic Flow Augmentation
1.0-1.5 lpm augmented blood flow

Locations

Country Name City State
United States University of California at San Diego San Diego California

Sponsors (1)

Lead Sponsor Collaborator
Orqis Medical Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Alive, Number of days out of the hospital, not on mechanical assistance over 35 day period. 35 days Yes
See also
  Status Clinical Trial Phase
Completed NCT01357850 - A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure Phase 2
Recruiting NCT00532688 - N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure Phase 2/Phase 3
Terminated NCT00383630 - Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure Phase 2
Completed NCT00531661 - CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients N/A
Completed NCT00159614 - Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment Phase 2
Completed NCT00149435 - Cardiovascular Health Study (CHS) Events Follow-up Study
Completed NCT00241761 - Epidemiology of Depression and Heart Failure in Aging N/A
Terminated NCT00125437 - Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy N/A
Completed NCT00094263 - Long-Term Predictors of Morbidity in Older Age N/A
Completed NCT00202579 - Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure Phase 2
Completed NCT00048425 - Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure. Phase 3
Completed NCT00023556 - Genetic Architecture of Heart Disease in Rural Brazil N/A
Completed NCT00530426 - Heart Failure Registry Phase 4
Terminated NCT00190359 - Growth Hormone and Heart Failure N/A
Completed NCT00004562 - Occluded Artery Trial (OAT) Phase 3
Completed NCT00005265 - Natural History of Coronary Heart Disease N/A
Completed NCT02772068 - Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a Early Phase 1
Completed NCT02925546 - A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets Phase 1
Completed NCT01074307 - A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea Phase 4
Completed NCT00502255 - Telemonitoring in Patients With Heart Failure N/A

External Links